Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
Active, not recruiting · Phase 1 · NCT03993873
Conditions: Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
At a glance
- Research payments reported, 2025
- $2,340
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 95
About the trial
- Sponsor
- Turning Point Therapeutics, Inc.
- Tested
- elzovantinib (TPX-0022) (drug)
- Dates
- Started 2019-09-05; completion 2027-03-03
- Results posted
- Not yet
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)
From ClinicalTrials.gov, last updated 2025-10-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $2,340 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute, Llc $2,340
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.